Clinical bottom line
Inherited disorders of glycosylation (CDG) represent a heterogeneous group of rare multisystem diseases caused by defects in glycan synthesis and attachment to proteins and lipids. These disorders often present with complex neurological, hepatic, gastrointestinal, and endocrine manifestations, frequently including developmental delay, hypotonia, and multisystem organ involvement. Clinical recognition remains challenging due to phenotypic variability and overlap with other metabolic and neurodegenerative conditions. Current evidence underscores the importance of a multidisciplinary approach incorporating biochemical testing, genetic confirmation, and supportive management tailored to organ-specific complications. While no curative therapies exist for most CDG subtypes, early diagnosis can guide symptomatic treatment and genetic counseling. Emerging insights into pathophysiology and novel biomarkers may improve diagnostic accuracy and therapeutic targeting in the future (Sparks et al., 2007; Sparks et al., 2024).
What the evidence shows
Disorders of glycosylation disrupt the normal post-translational modification of proteins and lipids, leading to multisystem dysfunction. The clinical spectrum ranges from severe congenital presentations with multisystem failure to milder late-onset phenotypes. Neurological involvement is nearly universal, often manifesting as cerebellar atrophy, developmental delay, seizures, and peripheral neuropathy (Sparks et al., 2007; Sparks et al., 2024). Peripheral nerve involvement, including demyelinating neuropathy, has been documented in hereditary multisystem degenerative disorders, highlighting the need for neurophysiological assessment in suspected cases (Author et al., 2013).
Liver dysfunction, coagulopathy, and endocrine abnormalities such as hypothyroidism and hypogonadism are common systemic features (White et al., 2020). Gastrointestinal symptoms including feeding difficulties and failure to thrive frequently complicate the clinical course. The phenotypic overlap with other inherited metabolic disorders necessitates comprehensive biochemical screening, including transferrin isoform analysis and glycan profiling, to identify glycosylation defects (White et al., 2020; Sparks et al., 2007).
Genetic testing has become the diagnostic gold standard, with next-generation sequencing panels enabling identification of pathogenic variants in multiple CDG-related genes. However, genotype-phenotype correlations remain incomplete, and some variants of uncertain significance require functional validation (Sparks et al., 2007; Sparks et al., 2024).
Management is largely supportive and symptom-directed. Multidisciplinary care involving neurology, hepatology, endocrinology, nutrition, and rehabilitation services is essential. Specific therapies such as mannose supplementation have shown benefit in select CDG subtypes (e.g., MPI-CDG), but evidence for disease-modifying treatments in most forms is limited (White et al., 2020). Emerging research into molecular mechanisms and potential targeted therapies is ongoing (Sparks et al., 2024).
Caveats and uncertainty
The rarity and clinical heterogeneity of CDG complicate epidemiological characterization and evidence synthesis. Many published reports are case series or small cohorts, limiting generalizability. Diagnostic delays remain common due to nonspecific early symptoms and lack of awareness. Biochemical assays can yield false negatives or inconclusive results, especially in milder or atypical phenotypes, necessitating cautious interpretation (Sparks et al., 2007).
Genetic testing may identify variants of uncertain significance, and functional studies are often required to confirm pathogenicity. The natural history of many CDG subtypes is incompletely understood, and long-term outcome data are sparse. Therapeutic interventions beyond supportive care lack robust clinical trial evidence, underscoring the need for collaborative registries and prospective studies (Sparks et al., 2024).
How this may change practice
Heightened clinical suspicion for CDG in patients with unexplained multisystem involvement, particularly neurological and hepatic features, should prompt early biochemical and genetic evaluation. Incorporating transferrin glycoform analysis and targeted gene panels into diagnostic algorithms may shorten the diagnostic odyssey. Multidisciplinary care models are recommended to address the complex needs of affected individuals.
Clinicians should be aware of emerging subtype-specific therapies and consider referral to specialized centers for access to experimental treatments and clinical trials. Genetic counseling is critical for affected families given the inherited nature and variable expressivity of these disorders. Ongoing research into biomarkers and molecular therapies holds promise to transform future management paradigms.